PBPK Applications (MIFD) Using the Simcyp® Simulator eBook PBPK Applications (MIFD) Using the Simcyp® Simulator Explores strategies, regulatory validation, and solutions in small-molecule human Physiologically Based Pharmacokinetic modeling (PBPK).Certara2024 年 8 月 28 日
Certara’s Integrated, Compliant Clinical Data Solution From Trial to Regulatory Submission Guide Certara 从试验到监管提交的综合、合规临床数据解决方案 点击以下任一步骤,了解更多信息。Certara2024 年 8 月 28 日
《降低通胀法案》对生物类似药市场有何影响? 博客 《降低通胀法案》对生物类似药市场有何影响? The Inflation Reduction Act (IRA), one of the key legislative achievements the Biden-Harris administration, aims…Certara2024 年 8 月 27 日
FDA’s Lykos Rejection Delays—But Doesn’t Stop—Psychedelic Therapies Press Coverage FDA 对 Lykos 的拒绝延缓了迷幻疗法的发展 — 但并未阻止其步伐 Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Certara2024 年 8 月 26 日
Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system qualification of the Simcyp Simulator Publication 预测涉及抑制作用的 CYP 介导的 DDIs:满足 Simcyp Simulator 系统鉴定要求的方法 The article "Prediction of CYP-mediated DDIs involving inhibition: Approaches to address the requirements for system…Certara2024 年 8 月 26 日
Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) Publication Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL) to Nonalcoholic Steatohepatitis (NASH) The article “Considerations for Physiologically Based Modeling in Liver Disease: From Nonalcoholic Fatty Liver (NAFL)…Certara2024 年 8 月 26 日
The Uncertain Path Forward for Psychedelic Medicine Press Coverage The Uncertain Path Forward for Psychedelic Medicine Certara's Dr. Fran Brown, Senior Vice President of Drug Development Science, is quoted in this…Certara2024 年 8 月 26 日